Abstract: Background: There are scarce studies in the literature about hyaluronic acid in systemic autoimmune myopathies. oBjectives: To analyze the serum level of hyaluronic acid in patients with dermatomyositis and polymyositis. Methods: Cross-sectional study, single-center, that evaluated hyaluronic acid in 18 dermatomyositis and 15 polymyositis (Bohan and Peter criteria), newly diagnosed, with clinical and laboratory activity, with no previous drug treatment. The patients were also age-, gender-and ethnicity-matched to 36 healthy individuals. The hyaluronic acid was analyzed by ELISA/EIA kit anti-hyaluronic acid. results: There was a higher serum level of hyaluronic acid in patients with autoimmune myopathies, in relation to control group (P<0.05). Moreover, the serum level of this glycosaminoglycan was higher in dermatomyositis, when compared to polymyositis. Both groups were comparable with regard to demographic, clinical and laboratory data, except for the presence of skin lesions in the first group. study liMitations. The presence of hyaluronic acid in cutaneous lesions, particularly of patients with dermatomyositis, was not analyzed neither quantified. In addition, due to disease rarity and the establishment of strict inclusion and exclusion criteria, there was a small sample in the present study. conclusions: As an example of others systemic autoimmune diseases, it is possible that the hyaluronic acid is involved in the pathogenesis of autoimmune myopathies, and particularly when associated with cutaneous lesions. Gottron's papules.
INTRODUCTION
Dermatomyositis (DM) and polymyositis (PM) are idiopathic inflammatory myopathies, characterized by progressive symmetrical and predominantly proximal muscle weakness. Additionally, DM has multiple cutaneous presentations, such as heliotrope, Gottron's papules, periungual hyperemia, "mechanic hands", ulcers, vasculitis, V-neck sign, shawl sign, calcinosis, Raynaud phenomenon, among others.
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Hyaluronic acid (HA) is one of the main elements of the extracellular matrix, with a substantive participation in the synovium, such as lubrication of the joints, hydration and supply of a matrix that allows cellular migration. 5 HA does not only provide a structure that allows the internal growth of fibroblasts and blood vessels, but also regulates multiple aspects of cellular mechanisms related to tissue repair, such as the activation of inflammatory cells to induce the immunological response. 5 Different studies have observed the rise in serum levels of HA in many systemic autoimmune conditions, including systemic sclerosis, psoriatic arthritis and systemic lupus ertythematosus. [6] [7] [8] [9] However, the study of HA in DM and PM is scarce.
9-13
The first descriptions related to the rise in HA serum levels in patients with DM were by Kubo et al. 10, 11 However, in one of the studies, these authors only followed two patients, both Asians, and one of them had malignancy-associated DM; in addition, these patients had a decrease in disease activity and of HA levels after the use of glucocorticoids. Gottron's papules.
Patients had less than 1 year between the diagnosis and the onset of disease, defined in this study as recently diagnosed, and had no previous drug treatment specific for muscle disease.
During the period of clinical and laboratory investigation, malignancies and/or infectious causes were excluded. Moreover, as the internal protocol of the Service, blood samples were collected from the patients and immediately centrifuged at 4ºC, 3000rpm for 15 minutes and stored in a freezer at -80°C. Thirty-six healthy adult voluntaries were included as the control group, matched by sex, age and ethnicity, for the same period of the study. were considered significant. All analyses were performed with SPSS 15.0 statistical software (Chicago, EUA). Victorino et al. 12 observed a strong association between HA and cutaneous lesions found in DM (photosensitivity, V-neck sign, shawl sign, periungual telangiectasia). Silva et al. 13 noted a positive correlation between the serum level of HA and the activity of patients with PM. However, these authors evaluated patients with and without disease activity, and only under different therapeutic regimens with glucocorticoids and/or immunosuppressants. 12, 13 In the present study, an association between HA and the different disease parameters was not observed, probably due to the fact that only patients with disease activity (DM or PM) were included. In contrast, because the level of HA was higher in DM than in PM, it is possible to deduct that this glycosaminoglycan is involved not only in the physiopathogenesis of both conditions, but also in the cutaneous lesions of DM.
RESULTS
Many studies have observed the rise in serum levels of HA in other systemic autoimmune conditions such as systemic sclerosis, systemic lupus erythematosus and psoriatic arthritis. [6] [7] [8] [9] In the latter, HA, besides being present in increased serum levels, correlated to the cutaneous changes, but not to joint involvement. 5 Chang et al. 9 observed HA accumulation, as well as chondroitin sulfate, specifically in cutaneous lesions from patients with systemic lupus erythematosus and also DM.
HA is a component of the connective tissue matrix and can also be found in the intercellular space and papillary dermis. As a study limitation, the presence of HA was not analyzed nor quantified in cutaneous lesions, particularly in DM patients and, due to the rarity of the condition and strict inclusion and exclusion criteria, there was a small sample in this study.
CONCLUSION
Increased serum levels of HA are found in patients with DM and PM when compared to healthy individuals. These findings can be associated to the pathophysiological process of these conditions. Most importantly, HA serum levels are increased in DM when compared to PM patients, possibly associated to cutaneous lesions.
However, further prospective studies are needed for the better understanding of its true physiopathogenic mechanism. q
